Endocannabinoid synthesis

Class

Endocannabinoid modulator

Notes

original target text: Endocannabinoid synthesis pathway

The endocannabinoid system relies on lipid signaling molecules, chiefly anandamide and 2-arachidonoylglycerol (2-AG), that are produced on demand from membrane lipid precursors by dedicated biosynthetic enzymes rather than being stored in vesicles like classical neurotransmitters. These endocannabinoids act locally, often signaling backward from a postsynaptic neuron to a presynaptic terminal, where they engage cannabinoid receptors CB1 and CB2 to dampen further neurotransmitter release or influence immune cell activity. Modulating the synthesis step, rather than blocking degradation or directly stimulating the receptors, offers a way to raise or lower endocannabinoid tone in a more spatially and temporally restricted manner, potentially reducing the risk of the broad central nervous system effects seen with direct cannabinoid receptor agonists. This approach is of interest across a range of conditions where endocannabinoid signaling is implicated, including chronic pain, inflammation, neurodegenerative and neuropsychiatric disorders, and metabolic regulation involving appetite and energy balance. Because the synthesis enzymes are shared entry points into a signaling cascade with wide physiological reach, agents acting here are generally designed to fine-tune, rather than switch on or off, the pathway.